Patent intelligence · US
US 7078412
Quinuclidine derivatives and medicinal compositions containing the same
Quinuclidine derivatives and medicinal compositions containing the same
Patent details — US 7078412
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jul 18, 2006
- Expiration
- Jul 13, 2026
- Applicant
- Almirall Prodesfarma S.A.
- Claims
- 10
- CPC classes
- A61K, A61K31/439, A61K31/4745, A61K31/56
Quick answer
US 7078412 (Quinuclidine derivatives and medicinal compositions containing the same) is held by Almirall Prodesfarma S.A.. Status: granted. Granted Jul 18, 2006. Expires Jul 13, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Almirall Prodesfarma S.A.
- Grant date
- Expiration
- Claims
- 10
- CPC classes
- A61K, A61K31/439, A61K31/4745, A61K31/56, A61K45/06, A61K47/26
More from Almirall Prodesfarma S.A.
Related pharmaceutical patents in our USPTO index.
-
US 12421228
Naphthyridine derivatives as PRC2 inhibitors
granted -
US 12421253
Tetrahydropyridopyrimidine pan-KRas inhibitors
granted -
US 12414911
Topical compositions and methods of use
granted -
US 12412764
Substrate-accommodating container
granted -
US 12398154
Azaquinazoline pan-KRas inhibitors
granted -
US 12383503
Adagrasib solid pharmaceutical compositions
granted -
US 12377101
Combination therapies
granted -
US 12371435
Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors
granted
Frequently asked questions
What is US patent 7078412?
US 7078412 (Quinuclidine derivatives and medicinal compositions containing the same) is held by Almirall Prodesfarma S.A.. Status: granted. Granted Jul 18, 2006. Expires Jul 13, 2026 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7078412?
Almirall Prodesfarma S.A. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 308 pharmaceutical patents for this assignee.
When does US 7078412 expire?
Our index shows an expiration date of Jul 13, 2026 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.